Niaid-VRC-mrna vaccine capability establishment
Active Awarded Last action
- Contract number
- 75N91022F00013
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $25,098,522
Award facts
- Contract value 83% obligated
-
- $25,098,522.00 Current, with exercised options
- $30,320,960.00 Potential, with all options
- Completion date 53% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $4,351,301 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $4,193,757 | |
| Exercise an Option | $13,206,872 | |
| Original award | $3,346,592 |
About this award
The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on September 2, 2022, with a ceiling value of $30.32 million for mRNA vaccine capability establishment, under cost-plus-fixed-fee pricing.
Place of performance is Frederick, Maryland. The order's ultimate completion date is June 17, 2030. The work encompasses specialized manufacturing and platform development for mRNA vaccine production capability.
Service Contract Inventory reporting captures this order's actual invoiced activity across fiscal years 2022–2025. FY2022 invoiced $96 thousand across 97 contractor hours and 0.1 FTEs. FY2023 invoiced $1.4 million across 3,111 contractor hours and 1.5 FTEs. FY2024 invoiced $3.6 million across 9,879 contractor hours and 4.8 FTEs. FY2025 invoiced $3.2 million across 6.1 FTEs. Derived government-paid hourly rates declined from $993.26/hr in FY2022 to $360.34/hr in FY2024. No subcontractors were reported in FY2025; Leidos Biomedical Research self-performed all invoiced hours.
Quick answers
Who was awarded contract 75N91022F00013?
75N91022F00013 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 2, 2022.
How much is contract 75N91022F00013 worth?
The government has obligated $25,098,522 on 75N91022F00013. Its potential value, with all options, is $30,320,960.
Which agency awarded contract 75N91022F00013?
National Cancer Institute (National Institutes of Health) awarded 75N91022F00013, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91022F00013 an order under another contract?
Yes. 75N91022F00013 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00013 competed?
The extent of competition for 75N91022F00013 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award